Sunday, September 20, 2026

Aurora Cannabis Soars 12%+ Today: What's Driving The Surge?

ViaNews Editorial Team

September 15, 2023

Aurora Cannabis Soars 12%+ Today: What's Driving The Surge?

(VIANEWS) - Aurora Cannabis (NYSE: ACB) stock surged 12.69% at 14:02 EST on Friday to EUR0.95, extending its gains over the previous two sessions. Meanwhile, as measured by the NYSE, broader market fell 0.4% to EUR16,024.90 after showing signs of bullish momentum during previous trading session; current session is showing declining trend.

About Aurora Cannabis

Aurora Cannabis Inc. produces and distributes medical and recreational cannabis products both domestically and abroad, through three segments - Canadian Cannabis, European Cannabis and Plant Propagation. Aurora also distributes wholesale medical cannabis in Europe and various international markets, as well as hemp-derived CBD products. Aurora cultivates and sells dried cannabis as well as oils, edibles, extracts and soft gels designed for smoking or vaping use. Aurora Cannabis Inc. offers an adult-use brand portfolio, such as Aurora Drift, San Rafael '71 Daily Special Whistler Being and Greybeard for adult consumers; CBD brands including Reliva and KG7; as well as medical cannabis brands including MedReleaf CanniMed Aurora Whistler Medical Marijuana Co Pedanios Bidiol CraftPlant among many others. Aurora Cannabis Inc is headquartered in Leduc, Canada.

Technical Analysis

Aurora Cannabis stock has experienced high trading volume recently, with today's reported volume totalling 810,692,830 being 433.42% above its average volume of 151,979,000. This increase may signal increased interest and activity surrounding Aurora Cannabis' stock, potentially leading to further price fluctuation. Aurora Cannabis's volatility has been on an overall upward trend over time. Last week, Aurora Cannabis experienced an average intraday volatility rate of 19.18%; last month it stood at 3.06% and last quarter at 4.55%. Yet even with such stability Aurora Cannabis experienced its highest average weekly volatility amplitude ever last week (32.52%), suggesting potential price swings in near future. According to the stochastic oscillator, an indicator for overbought and oversold conditions, Aurora Cannabis stock is currently considered overbought (>=80), suggesting it could be in need of correction or consolidation which may eventually lead to a drop in price. Aurora Cannabis stock is currently experiencing high trading volume and volatility, as well as potential price fluctuations that warrant additional attention from investors. Any investors considering Aurora's stock should exercise caution, taking note of its overbought status before making investment decisions.

Equity Analysis

Aurora Cannabis's trailing twelve months EPS of EUR-6.15 indicates a loss per share over the past year due to factors including high operating expenses, reduced revenue or investments made into growth initiatives. Aurora Cannabis is an emerging company in the cannabis industry and still in its early stages, so they may be investing heavily in research and development, marketing efforts, or expansion of production facilities. Investors should carefully assess a company's growth prospects, competitive position, and overall financial health before making investment decisions. Furthermore, it's wise to monitor earnings reports and other financial metrics closely in order to track its progress over time.

More news about Aurora Cannabis (ACB).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com